Small molecule ligands for oxytocin and vasopressin receptors

✍ Scribed by Roger M. Freidinger; Douglas J. Pettibone

• Publisher: John Wiley and Sons
• Year: 1997
• Tongue: English
• Weight: 332 KB
• Volume: 17
• Category: Article
• ISSN: 0198-6325
• DOI: 10.1002/(sici)1098-1128(199701)17:1<1::aid-med1>3.0.co;2-5

✦ Synopsis

postdoctoral years at the Uniformed Services University in Bethesda, Maryland where he studied the neuroendocrine control of beta-endorphin release from the pituitary gland. In 1982, he joined Merck Research Laboratories where he is currently Director of Biochemical Pharmacology. His professional interests include the development of novel therapeutic agents targeting G-protein coupled receptors. Roger M. Freidinger received a B.S. in chemistry from the University of Illinois in 1969 and a Ph.D. in organic chemistry from the Massachusetts Institute of Technology in 1975. Since 1975, he has been at the Merck Research Laboratories in West Point, Pennsylvania, where he is currently Executive Director in Medicinal Chemistry. His research has encompassed several therapeutic areas involving chemistry of peptides, peptidomimetics, and small molecule ligands for peptide receptors. Specific examples are orally active nonpeptide cholecystokinin and oxytocin antagonists.